


## DPTIP-prodrug 18

Cat. No.:	HY-149025
CAS No.:	2881068-33-1
Molecular Formula:	C <sub>36</sub> H <sub>44</sub> N <sub>4</sub> O <sub>4</sub> S
Molecular Weight:	628.82
Target:	Phospholipase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	DPTIP-proagent 18 (P18) is a orally active and brain-penetrable proagent of <a href="#">DPTIP</a> (HY-131002). DPTIP-proagent 18 is a potent nSMase2 inhibitor. DPTIP-proagent 18 significantly inhibits IL-1 $\beta$ -induced EV (extracellular vesicle) release by inhibition of nSMase2 (neutral sphingomyelinase-2) activity. DPTIP-proagent 18 can be used for brain injury research <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	nSMase2 <sup>[1]</sup>																
<b>In Vitro</b>	DPTIP-prodrug 18 is metabolically stable with >75% intact prodrug remaining after 1 h of incubation at 37 °C <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>DPTIP-prodrug 18 exhibits an excellent PK profile<sup>[1]</sup>.  DPTIP-prodrug 18 shows significant inhibition of nSMase2 activity and IL-1<math>\beta</math>-induced EV release in mice<sup>[1]</sup>.  MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CES1<sup>-/-</sup> mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg DPTIP equivalent</td> </tr> <tr> <td>Administration:</td> <td>Orally, once (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>Exhibited &gt;fourfold higher plasma (AUC<sub>0-t</sub>=1047 pmol·h/mL) and brain exposures (AUC<sub>0-t</sub>=247 pmol·h/g) versus DPTIP and a significant enhancement of DPTIP half-life (2 h vs ~0.5 h).</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Interleukin-1<math>\beta</math>-injected mice (a mouse model of brain injury)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0, 3 and 10 mg/kg (DPTIP equivalent)</td> </tr> <tr> <td>Administration:</td> <td>Orally, once</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited the release of brain-derived GFP+ EVs into the blood at both 3 and 10 mg/kg (DPTIP equivalent dose).</td> </tr> </table>	Animal Model:	CES1 <sup>-/-</sup> mice <sup>[1]</sup>	Dosage:	10 mg/kg DPTIP equivalent	Administration:	Orally, once (Pharmacokinetic Analysis)	Result:	Exhibited >fourfold higher plasma (AUC <sub>0-t</sub> =1047 pmol·h/mL) and brain exposures (AUC <sub>0-t</sub> =247 pmol·h/g) versus DPTIP and a significant enhancement of DPTIP half-life (2 h vs ~0.5 h).	Animal Model:	Interleukin-1 $\beta$ -injected mice (a mouse model of brain injury) <sup>[1]</sup>	Dosage:	0, 3 and 10 mg/kg (DPTIP equivalent)	Administration:	Orally, once	Result:	Significantly inhibited the release of brain-derived GFP+ EVs into the blood at both 3 and 10 mg/kg (DPTIP equivalent dose).
Animal Model:	CES1 <sup>-/-</sup> mice <sup>[1]</sup>																
Dosage:	10 mg/kg DPTIP equivalent																
Administration:	Orally, once (Pharmacokinetic Analysis)																
Result:	Exhibited >fourfold higher plasma (AUC <sub>0-t</sub> =1047 pmol·h/mL) and brain exposures (AUC <sub>0-t</sub> =247 pmol·h/g) versus DPTIP and a significant enhancement of DPTIP half-life (2 h vs ~0.5 h).																
Animal Model:	Interleukin-1 $\beta$ -injected mice (a mouse model of brain injury) <sup>[1]</sup>																
Dosage:	0, 3 and 10 mg/kg (DPTIP equivalent)																
Administration:	Orally, once																
Result:	Significantly inhibited the release of brain-derived GFP+ EVs into the blood at both 3 and 10 mg/kg (DPTIP equivalent dose).																

---

## REFERENCES

---

[1]. Pal A, et al. Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP. J Med Chem. 2022 Aug 5.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA